These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37154894)

  • 1. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges.
    Al-Ani A; Chen JJ; Costello F
    J Neurol; 2023 Aug; 270(8):4132-4150. PubMed ID: 37154894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
    Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-lasting pain and somatosensory disturbances in children with myelin oligodendrocyte glycoprotein antibody-associated disease.
    Ichimiya Y; Chong PF; Sonoda Y; Tocan V; Watanabe M; Torisu H; Kira R; Takahashi T; Kira JI; Isobe N; Sakai Y; Ohga S
    Eur J Pediatr; 2023 Jul; 182(7):3175-3185. PubMed ID: 37119299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing.
    Sechi E; Buciuc M; Pittock SJ; Chen JJ; Fryer JP; Jenkins SM; Budhram A; Weinshenker BG; Lopez-Chiriboga AS; Tillema JM; McKeon A; Mills JR; Tobin WO; Flanagan EP
    JAMA Neurol; 2021 Jun; 78(6):741-746. PubMed ID: 33900394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
    Ambrosius W; Michalak S; Kozubski W; Kalinowska A
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria.
    Banwell B; Bennett JL; Marignier R; Kim HJ; Brilot F; Flanagan EP; Ramanathan S; Waters P; Tenembaum S; Graves JS; Chitnis T; Brandt AU; Hemingway C; Neuteboom R; Pandit L; Reindl M; Saiz A; Sato DK; Rostasy K; Paul F; Pittock SJ; Fujihara K; Palace J
    Lancet Neurol; 2023 Mar; 22(3):268-282. PubMed ID: 36706773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High titers of myelin oligodendrocyte glycoprotein antibody are only observed close to clinical events in pediatrics.
    Lui A; Chong J; Flanagan E; Abrams AW; Krysko KM; Arikan B; Francisco C; Rutatangwa A; Waubant E; Ziaei A
    Mult Scler Relat Disord; 2021 Nov; 56():103253. PubMed ID: 34517190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MOGAD Involving Cranial Neuropathies: A Case Report and Review of Literature.
    Du Y; Xiao L; Ding Z; Huang K; Xiao B; Feng L
    Brain Sci; 2022 Nov; 12(11):. PubMed ID: 36421853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management.
    Sechi E; Cacciaguerra L; Chen JJ; Mariotto S; Fadda G; Dinoto A; Lopez-Chiriboga AS; Pittock SJ; Flanagan EP
    Front Neurol; 2022; 13():885218. PubMed ID: 35785363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-based assays for the detection of MOG antibodies: a comparative study.
    Gastaldi M; Scaranzin S; Jarius S; Wildeman B; Zardini E; Mallucci G; Rigoni E; Vegezzi E; Foiadelli T; Savasta S; Banfi P; Versino M; Benedetti L; Novi G; Mancardi MM; Giacomini T; Annovazzi P; Baroncini D; Ferraro D; Lampasona V; Reindl M; Waters P; Franciotta D
    J Neurol; 2020 Dec; 267(12):3555-3564. PubMed ID: 32623596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory features distinguishing MOG antibody disease from multiple sclerosis and AQP4 antibody-positive neuromyelitis optica.
    Ciotti JR; Eby NS; Wu GF; Naismith RT; Chahin S; Cross AH
    Mult Scler Relat Disord; 2020 Oct; 45():102399. PubMed ID: 32702642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
    Kwon YN; Kim B; Ahn S; Seo J; Kim SB; Yoon SS; Sung JJ; Choi YS; Kim SM
    J Neuroimmunol; 2020 Nov; 348():577361. PubMed ID: 32919144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient Pathway to Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): Findings from a Multinational Survey of 204 Patients.
    Santoro JD; Gould J; Panahloo Z; Thompson E; Lefelar J; Palace J
    Neurol Ther; 2023 Aug; 12(4):1081-1101. PubMed ID: 37024731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution in anti-myelin oligodendrocyte glycoprotein antibody detection and its clinical significance: a narrative review.
    Zhong X; Wang Y; Luo W; Ma X; Sun X; Jiang B; Qiu W
    Ann Transl Med; 2023 Apr; 11(7):287. PubMed ID: 37090054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD.
    Lin L; Wu Y; Hang H; Lu J; Ding Y
    Front Immunol; 2022; 13():853891. PubMed ID: 35898513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features and Imaging Findings of Myelin Oligodendrocyte Glycoprotein-IgG-Associated Disorder (MOGAD).
    Li Y; Liu X; Wang J; Pan C; Tang Z
    Front Aging Neurosci; 2022; 14():850743. PubMed ID: 35370624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathology of central nervous system inflammatory demyelinating disease accompanying myelin oligodendrocyte glycoprotein autoantibody.
    Höftberger R; Guo Y; Flanagan EP; Lopez-Chiriboga AS; Endmayr V; Hochmeister S; Joldic D; Pittock SJ; Tillema JM; Gorman M; Lassmann H; Lucchinetti CF
    Acta Neuropathol; 2020 May; 139(5):875-892. PubMed ID: 32048003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.